Magnetic resonance spectroscopy of premalignant and malignant endometrial disorders: a feasibility of in vivo study

Basit Öğe Kaydı
dc.authorwosidSaraç, Kaya/ABI-1091-2020
dc.contributor.authorCelik, O
dc.contributor.authorHascalik, S
dc.contributor.authorSarac, K
dc.contributor.authorMeydanli, MM
dc.contributor.authorAlkan, A
dc.contributor.authorMizrak, B
dc.date.accessioned2024-08-04T20:13:41Z
dc.date.available2024-08-04T20:13:41Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: To assess the potential clinical utility of in vivo proton magnetic resonance spectroscopy (MRS) in patients with various endometrial lesions. Methods: Twelve patients with untreated uterine bleeding were included in this study. In-vivo proton MRS was performed using a 1.5 T MR scanner. The metabolite levels were classified into three classes in comparison with the noise level by visual examination. All the patients have endometrial biopsy. For each type of lesions, chemical compound were described. Results: Pathological examination resulted in three endometrial cancer, two simple hyperplasias, one complex hyperplasia, two partial hydatiform mole, two proliferative endometrium and two secretory endometrium. In women with endometrial carcinoma, high choline and lipid signals were detected, whereas no creatine and no lactate signals were found. In women with endometrial hyperplasia, choline signal was detectable in all cases but one case showed lactate signal in addition to choline. In women with partial hydatidiform mole, the only detectable signal was choline. Lipid signals were detected in none of the cases with endometrial hyperplasia and partial hidatidiform mole. In women with either secretory or proliferative endometrium, choline and lactate signals were detectable in all cases but one case showed solely choline. Lipid signals were not deteced in any of subjects with secretory or proliferative endometrium. Conclusion: The observed difference is the presence of lipid signal only in endometrial carcinoma. (C) 2004 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.ejogrb.2004.06.030
dc.identifier.endpage245en_US
dc.identifier.issn0301-2115
dc.identifier.issn1872-7654
dc.identifier.issue2en_US
dc.identifier.pmid15653212en_US
dc.identifier.scopus2-s2.0-11844282701en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage241en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejogrb.2004.06.030
dc.identifier.urihttps://hdl.handle.net/11616/93779
dc.identifier.volume118en_US
dc.identifier.wosWOS:000226596000020en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal of Obstetrics & Gynecology and Reproductive Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectspectroscopyen_US
dc.subjectmagnetic resonanceen_US
dc.subjectendometrial carcinomaen_US
dc.titleMagnetic resonance spectroscopy of premalignant and malignant endometrial disorders: a feasibility of in vivo studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu